What is true about HER2/neu overexpression in Ca breast
Correct Answer: Responds well to monoclonal antibodies
Description: .* Tumour grade, growth factor and oncogene factors. ErbB2 -Her-2/neu positive has got poor prognosis. ErbB1 with over expression of epidermal growth factor (EGF), TGF alpha and cathepsin D has got poor prognosis. * Progesterone receptor (PR status) study or Her 2 Neu receptor status or cErb B2 (growth factor receptor study) are other studies done at present to plan the therapy and assess the prognosis. TRANSTUZUMAB (Herceptin)- * It is a monoclonal antibody that blocks HER-2/neu receptors thereby preventing growth of cancer cells. It is a new drug. It is presently marketed as herceptin. It is c-ErbB2 (growth factor receptor) inhibitor. It is a newer biological agent. * It has very little effect on HER-2/neu negative cancers. * It is useful only in HER-2/neu positive cancers. It is currently approved by FDA for use only in metastatic disease. It is given as intravenous infusion. ref:SRB&;s manual of surgery,ed 3,pg no 486
Category:
Surgery
Get More
Subject Mock Tests
Practice with over 200,000 questions from various medical subjects and improve your knowledge.
Attempt a mock test nowMock Exam
Take an exam with 100 random questions selected from all subjects to test your knowledge.
Coming SoonGet More
Subject Mock Tests
Try practicing mock tests with over 200,000 questions from various medical subjects.
Attempt a mock test now